BPC-157's potential to stimulate angiogenesis helps in effective healing and recovery
Six trials involving approximately 900 participants confirmed no treatment-related serious adverse events, no IGF-1 elevation, no cardiovascular events, and no immunogenic response
SAME DAY DELIVERY: If order has been placed before 12pm the same day, we can deliver same day but not guaranteed, still depends on location if courier can deliver
How often it happens The rates vary by trial and population: 2,3 TRIUMPH-4 (obesity with knee osteoarthritis): 8.8% on 9 mg, 20.9% on 12 mg, 0.7% on placebo TRANSCEND-T2D-1 (type 2 diabetes): 4.5% on 4 mg, 2.3% on 9 mg, 4.4% on 12 mg, 0% on placebo Phase 2 trial (Jastreboff 2023): not reported The TRIUMPH-4 numbers are markedly higher than those of TRANSCEND-T2D-1
The nevus originates from the proliferation of melanocytes
doi: 10.1016/j.expneurol.2013.11.001 103 XuKXuYBrown-JermynDChenJ-FAscherioADluzenDEet al